Table 1. Patient characteristics.
| 3A | 20A | P value | |
|---|---|---|---|
| Number | 24 | 56 | |
| Median age (range) | 40 (16-59) | 47.5 (15-63) | 0.060 |
| Sex | |||
| Male/Female | 12/12 | 35/21 | 0.33 |
| Disease | 0.52 | ||
| AML | 10 | 27 | |
| ALL | 2 | 8 | |
| MDS/MPD | 3 | 9 | |
| ML/MM | 5 | 9 | |
| sAA | 4 | 3 | |
| Disease status | 0.86 | ||
| CR1 | 6 | 16 | |
| CR2-4 | 6 | 15 | |
| relapse/refractory | 5 | 14 | |
| primary therapy | 7 | 11 | |
| Performance status | 0.087 | ||
| 0/1 | 22 | 56 | |
| 2/4 | 2 | 0 | |
| Donor source | 0.078 | ||
| BM | 18 | 51 | |
| PB | 6 | 5 | |
| HLA compatibility | 0.0256 | ||
| Matched unrelated | 11 | 30 | |
| Mismatched unrelated | 5 | 21 | |
| Mismatched related | 8 | 5 | |
| Conditioning regimen | |||
| MAC | 16 | 29 | 0.325 |
| RIC | 8 | 27 | |
| TBI/nonTBI | 19/5 | 40/16 | 0.59 |
| Use of ATG | 0.19 | ||
| Yes | 4 | 3 | |
| No | 20 | 53 | |
| GVHD prophylaxis | 0.096 | ||
| CYA-based | 23 | 45 | |
| TAC-based | 1 | 11 | |
| Recipient / Donor CMV status | 0.24 | ||
| Pos. / Pos. | 14 | 31 | |
| Pos. / Neg. | 5 | 21 | |
| Neg. / Pos. | 4 | 4 | |
| Missing. / Pos. | 1 | 0 | |
| Acute GVHD | 0.63 | ||
| grade 0-1 | 12 | 32 | |
| grade 2-4 | 12 | 24 | |
| Use of steroids | 0.45 | ||
| Yes | 17 | 33 | |
| No | 7 | 23 |
AML: acute myeloid leukemia, ALL: acute lymphoblastic lymphoma, MDS: myelodysplastic syndrome, MPD: myeloproliferative disease, ML: malignant lymphoma, MM: multiple myeloma, sAA: severe aplastic anemia, CR: complete response, BM: bone marrow, PB: peripheral blood, MAC: myeloablative conditioning, RIC: reduced-intensity conditioning, ATG: antithymoglobulin, GVHD: graft-versus-host disease, CYA: cyclosporine, TAC: tacrolimus, Pos: positive, Neg: negative